Skip to content

Alignment Healthcare

US · ALHC #2907 by market cap Listed 2021
8.55 +0.18 +2.15%
Live - 5344 symbols - heartbeat 475s ago · 2026-10-08 05:07
Pre-market 8.69 +1.64%
After-hours 8.57 +0.23%
Overnight 8.57 +0.23%
Market cap
1.77B
P/B
6.69
EPS
0.00
Reader sentiment Are you bullish or bearish on ALHC?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 6.55 Cheap vs history 25th percentile
5-year average 13.61 · #11 of 11 in Healthcare Plans
P/E ratio 45.00 Expensive vs history 92nd percentile
5-year average -177.56 · forward 24.66 · #8 of 9 in Healthcare Plans
P/S ratio 0.38 Cheap vs history 1st percentile
5-year average 1.17 · forward 0.30 · #6 of 11 in Healthcare Plans

Vs. peers Healthcare Plans

Company Market cap P/E (TTM) P/B Div yield
Alignment Healthcare (ALHC) 1.77B 45.97 6.69 0.00%
UnitedHealth (UNH) 337.48B 24.16 3.43 2.38%
CVS Health (CVS) 112.49B 23.21 1.41 3.02%
Elevance Health (ELV) 87.68B 17.88 1.95 1.70%
Cigna Group (CI) 73.59B 11.52 1.73 2.20%
Humana (HUM) 47.61B 37.48 2.48 0.89%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value10.97 Economic moatNone UncertaintyHigh

Trading 28.3% below Morningstar's fair value estimate.

Fair value

Alignment Healthcare Inc is assigned a 4-star quantitative star rating, indicating our belief that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 24% discount to our quantitative fair value estimate of $10.97 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's profitability strengthens our valuation estimate. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. Reflecting the firm's profitability is its enterprise value to free cash flow ratio of 10.4, which lies in the bottom 20% compared with global peers. This can be a sign of operational efficiency and potential for the company to fund growth, pay dividends, or reduce debt without needing additional capital. We believe this is a sign that shares could be cheap.

The company's valuation metrics are an additional encouraging factor. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to EBITDA ratio of 8.5, a core component of valuation, lies in the bottom 30% globally. Relative to the company's EBITDA, the enterprise value of the business is low, which further promotes our favorable price/fair value ratio.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 05:07:43 · For reference only, not investment advice and not tailored to your situation.